CureVac NV
NASDAQ:CVAC
Intrinsic Value
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). [ Read More ]
The intrinsic value of one CVAC stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.48 USD, CureVac NV is hidden .
Valuation Backtest
CureVac NV
Run backtest to discover the historical profit from buying and selling CVAC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CureVac NV
Current Assets | 478.4m |
Cash & Short-Term Investments | 405.1m |
Receivables | 22.3m |
Other Current Assets | 51m |
Non-Current Assets | 309.9m |
PP&E | 278.6m |
Intangibles | 28.3m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 186.4m |
Accounts Payable | 48m |
Other Current Liabilities | 138.4m |
Non-Current Liabilities | 84.9m |
Long-Term Debt | 36.8m |
Other Non-Current Liabilities | 48.1m |
Earnings Waterfall
CureVac NV
Revenue
|
53.8m
EUR
|
Cost of Revenue
|
-116.3m
EUR
|
Gross Profit
|
-62.5m
EUR
|
Operating Expenses
|
-207.2m
EUR
|
Operating Income
|
-269.7m
EUR
|
Other Expenses
|
9.5m
EUR
|
Net Income
|
-260.2m
EUR
|
Free Cash Flow Analysis
CureVac NV
CVAC Profitability Score
Profitability Due Diligence
CureVac NV's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
CureVac NV's profitability score is hidden . The higher the profitability score, the more profitable the company is.
CVAC Solvency Score
Solvency Due Diligence
CureVac NV's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
CureVac NV's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CVAC Price Targets Summary
CureVac NV
According to Wall Street analysts, the average 1-year price target for CVAC is 9.27 USD with a low forecast of 2.63 USD and a high forecast of 18.9 USD.
Shareholder Return
CVAC Price
CureVac NV
Average Annual Return | -29.41% |
Standard Deviation of Annual Returns | 71.67% |
Max Drawdown | -98% |
Market Capitalization | 779.5m USD |
Shares Outstanding | 223 920 000 |
Percentage of Shares Shorted | 10.96% |
CVAC News
Last Important Events
CureVac NV
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
CureVac NV
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
Contact
IPO
Employees
Officers
The intrinsic value of one CVAC stock under the Base Case scenario is hidden USD.
Compared to the current market price of 3.48 USD, CureVac NV is hidden .